Enliven Corp (ELVN): Price Target Chart

Corporate company logo of Enliven Pharma (ELVN)

The biopharmaceutical business of Enliven Therapeutics (ELVN), which implements energy-efficient technologies and reduces chemical waste in laboratories, is represented by the market price visualization on GURU.Markets, where the indicator stands at 73.93. Enliven Therapeutics (ELVN) is relying on the acceleration of phase II tests for selective inhibitors to combat leukemia. A team of scientists, ensuring the transparency of trial data and a robust cash reserve, supports the project's success.

Enliven Therapeutics Inc - ELVN Price Target Chart (period 04/28/2023 - 11/13/2026)

Metric breakdowns and analytics for Enliven Pharma (ELVN)

- current quotes and average value forecast:
Market Price enliventherapeutics.com|ELVN - Price Target Chart
- stock exchange capitalization data:
Market Value Enliven Pharma|ELVN - Real Price to Acquire Entire Company
- issuer book value statistics:
Net Assets per Single Share Enliven Therapeutics|ELVN - Company Book Value|Capitalization to Book Value Ratio enliventherapeutics.com|ELVN - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Capital Enliven Therapeutics|ELVN - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Enliven Corp|ELVN - Company Aggregate Debts|Debt to Book Value Enliven Pharma|ELVN - Company Long-Term Debt|Short-Term Debt Enliven Therapeutics|Quick Liquidity enliventherapeutics.com
- financial results and valuation multiples details:
ELVN - Company Net Income|Expected Net Profit Enliven Therapeutics|ELVN - P/E Multiple|Forward Price to Earnings Multiple Enliven Therapeutics Inc|ELVN - Price/Earnings to Growth Multiple|Company Value to EBITDA Enliven Pharma|ELVN - Operating profit before deduction of amortization|Earnings per share for the trailing year Enliven Therapeutics|ELVN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months enliventherapeutics.com|ELVN - Earnings growth in current year|Earnings growth forecast for next year Enliven Therapeutics
General company analysis:ELVN (enliventherapeutics.com)
Mass-produced product of enliventherapeutics.com

Enliven Therapeutics (ELVN) is developing innovative targeted therapy methods in oncology. This indicator represents the average fair value of shares as calculated by independent experts. Analyzing the trend of the weighted average target allows for the identification of cash flow overvaluation relative to the cost of capital. Growth in this metric reflects market optimism regarding future earnings. The company's robust capital reserve minimizes risks, making such forecasts more grounded.

Competitors of Enliven Therapeutics

GMAB - Average Forecast Price|Price Target Chart Exelixis EXEL|Nuvalent Inc - Price Target Chart|KYMR: Consensus Target|IDYA: Price Target Chart|ORIC Pharmaceuticals (ORIC) - Price Target Chart|Broker Consensus Forecast RLAY|Price Target Chart Nurix Therapeutics, Inc.|Average Forecast Price Tyra Biosciences Inc TYRA|Price Target Chart Verastem Inc (VSTM)|Monte Rosa Corp - Broker Consensus Forecast|Analyst Consensus Forecast CGEM (Cullinan Therapeutics)|IMRX - Consensus Target|CCCC - Price Target Chart|Average Forecast Price Black Diamond Therapeutics, Inc.|Repare Rx (RPTX) - Price Target Chart|PMVP (PMV Pharmaceuticals, Inc) - Price Target Chart|Price Target Chart Karyopharm Therapeutics, Inc.|Average Forecast Price Propanc Biopharma, Inc. PPCB|Analyst Consensus Forecast BGMS|aadibio.com (AADI) - Analyst Target Range|Aileron Therapeutics, Inc. - Consensus Target|Blueprint Medicines Corp. (BPMC) - Average Forecast Price|GLYC: Consensus Target|Fair Value Consensus SWTX (springworkstx.com)